307 related articles for article (PubMed ID: 24301524)
1. Proteasome inhibitors exert cytotoxicity and increase chemosensitivity via transcriptional repression of Notch1 in T-cell acute lymphoblastic leukemia.
Koyama D; Kikuchi J; Hiraoka N; Wada T; Kurosawa H; Chiba S; Furukawa Y
Leukemia; 2014 Jun; 28(6):1216-26. PubMed ID: 24301524
[TBL] [Abstract][Full Text] [Related]
2. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
3. Augmented efficacy with the combination of blockade of the Notch-1 pathway, bortezomib and romidepsin in a murine MT-1 adult T-cell leukemia model.
Yu P; Petrus MN; Ju W; Zhang M; Conlon KC; Nakagawa M; Maeda M; Bamford RN; Waldmann TA
Leukemia; 2015 Mar; 29(3):556-66. PubMed ID: 25118879
[TBL] [Abstract][Full Text] [Related]
4. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid sensitivity of T-cell lymphoblastic leukemia/lymphoma is associated with glucocorticoid receptor-mediated inhibition of Notch1 expression.
Cialfi S; Palermo R; Manca S; Checquolo S; Bellavia D; Pelullo M; Quaranta R; Dominici C; Gulino A; Screpanti I; Talora C
Leukemia; 2013 Feb; 27(2):485-8. PubMed ID: 22846929
[No Abstract] [Full Text] [Related]
7. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
8. DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.
Minuzzo S; Agnusdei V; Pusceddu I; Pinazza M; Moserle L; Masiero M; Rossi E; Crescenzi M; Hoey T; Ponzoni M; Amadori A; Indraccolo S
Carcinogenesis; 2015 Jan; 36(1):115-21. PubMed ID: 25355291
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
10. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
[TBL] [Abstract][Full Text] [Related]
11. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
[TBL] [Abstract][Full Text] [Related]
12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity.
Salem K; Brown CO; Schibler J; Goel A
Exp Hematol; 2013 Feb; 41(2):209-18. PubMed ID: 23063726
[TBL] [Abstract][Full Text] [Related]
15. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia.
Marchesini M; Gherli A; Montanaro A; Patrizi L; Sorrentino C; Pagliaro L; Rompietti C; Kitara S; Heit S; Olesen CE; Møller JV; Savi M; Bocchi L; Vilella R; Rizzi F; Baglione M; Rastelli G; Loiacono C; La Starza R; Mecucci C; Stegmaier K; Aversa F; Stilli D; Lund Winther AM; Sportoletti P; Bublitz M; Dalby-Brown W; Roti G
Cell Chem Biol; 2020 Jun; 27(6):678-697.e13. PubMed ID: 32386594
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
[TBL] [Abstract][Full Text] [Related]
19. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms.
Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W
Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451
[TBL] [Abstract][Full Text] [Related]
20. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.
Lesovaya E; Yemelyanov A; Kirsanov K; Popa A; Belitsky G; Yakubovskaya M; Gordon LI; Rosen ST; Budunova I
Cell Cycle; 2013 Jan; 12(1):133-44. PubMed ID: 23255118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
